Medical condition
Diabetes
Diabetes is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- alogliptin (NESINA) Alimentary tract and metabolism (A10)
- saxagliptin (ONGLYZA) Alimentary tract and metabolism (A10)
- pioglitazone (ACTOS) Alimentary tract and metabolism (A10)
- dabigatran etexilate (DABIGATRAN ETEXILATE ACCORD) Blood and blood forming organs (B01)
- dapagliflozin (FORXIGA) Alimentary tract and metabolism (A10)
- apixaban (ELIQUIS) Blood and blood forming organs (B01)
- glucagon (BAQSIMI) Systemic hormonal preparations (H04)
- naltrexone (ARX-NALTREXONE) Alimentary tract and metabolism (A08)
- canagliflozin (INVOKANA) Alimentary tract and metabolism (A10)
- alogliptin benzoate (VIPIDIA) Alimentary tract and metabolism (A10)
- irbesartan (ABISART 150) Cardiovascular system (C09)
- linagliptin (TRAJENTA) Alimentary tract and metabolism (A10)
Latest Diabetes news
FDA Approves MannKind's Afrezza for Pediatric Diabetes Patients
The US FDA has approved MannKind's Afrezza inhaled insulin for pediatric patients aged 6 and older diagnosed with Type 1 or Type 2 diabetes. This approval marks a significant expansion for the inhaled insulin.
Tracking Cellular Disruptions in Type 1 Diabetes: Insights for Pharma
This article explores recent findings on cellular disruptions linked to type 1 diabetes and their implications for pharmaceutical development and investment.
FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Enters Diabetes Market
FDA approves LANGLARA as interchangeable biosimilar to Lantus insulin glargine, marking Lannett Company's entry into diabetes treatment market through Lanexa Biologics.
Novo Nordisk's Oral Ozempic Becomes First FDA-Approved Pill GLP-1 for Type 2 Diabetes with Cardiovascular Protection
Novo Nordisk's oral Ozempic pill receives FDA approval as the first oral GLP-1 medication for type 2 diabetes with cardiovascular risk reduction benefits.
Wave Life Sciences WVE-007 Phase 2a Trial Gets FDA Approval for Obesity and Type 2 Diabetes Treatment
Wave Life Sciences receives FDA acceptance for WVE-007 Phase 2a multidose trial targeting obesity and type 2 diabetes, set to begin Q2 2026.
Ascletis Completes Enrollment for ASC30 Oral GLP-1 Diabetes Drug Phase II Trial
Ascletis Pharma completes enrollment in Phase II trial of ASC30, an oral GLP-1 receptor agonist for diabetes treatment, with results expected Q3 2026.
Ascletis Completes Enrollment in Phase II Trial of ASC30 Oral GLP-1 Diabetes Drug
Ascletis Pharma completes enrollment of 100 patients in Phase II trial of ASC30, an oral GLP-1 receptor agonist for diabetes treatment, with results expected Q3 2026.
Novo Nordisk's Oral Semaglutide Shows Promise as First GLP-1 Therapy for Children with Type 2 Diabetes
Novo Nordisk's PIONEER TEENS trial demonstrates oral semaglutide significantly reduces blood sugar in children with type 2 diabetes, paving way for regulatory filings.